SVASE Event: 'BIG EVENT & Business Showcase: Life Sciences - Convergence Of Intelligent Systems In Drug-Device Combinations – The Shape Of Things To Come' May 17, 2007

SVASE Event: 'BIG EVENT & Business Showcase: Life Sciences - Convergence Of Intelligent Systems In Drug-Device Combinations – The Shape Of Things To Come'

Event: 'BIG EVENT & Business Showcase: Life Sciences - Convergence Of Intelligent Systems In Drug-Device Combinations – The Shape Of Things To Come'

Business Interface Groups – where Business & Technology collide!
Date: Thursday, May 17, 2007 At 06:00
Duration: 2 Hours 30 Minutes
Contact Info:
Cooley Godward Kronish LLP, 3175 Hanover Street, Palo Alto, CA 94304 Contact: Laura Weigant Email: [email protected]
URL: svase.org/index.php?option=com_extcalendar&Itemid=149&extmode=view&extid=896

A drug-Device combination, the healthy marriage of medical devices with drugs/biologics is an exciting new frontier with huge revenue potential. It can revolutionize medical treatments and re-invigorate existing drugs & devices while making current treatments obsolete. Combination products i.e., drug-device, drug-biologic, and device-biologic products, are increasingly incorporating cutting edge, novel technologies that hold great promise for advancing patient care. This new therapeutic modality is also rapidly narrowing the gap between Pharma, Biologics and Devices. Combination products, a multi-billion dollar opportunity, are an area of intense interest and unlimited potential from a clinical as well as an investment point of view.

With the approval of Johnson & Johnson’s Cypher drug-eluting stent and Boston Scientific’s Taxus drug-eluting stent, drug-device combination products have attracted medical and media attention. Today, combination products range from drug-eluting stents for coronary blockages, to drug-biological products, such as device-monoclonal antibodies for the treatment of cancer. Artificial organs and drugs on chips are other examples of such combination innovations.

How does it shape together?

In this event, our experienced panelists consisting of seasoned investors and entrepreneurs will brainstorm on the various aspects of the ‘combination world’. They will identify opportunities, hurdles, and regulatory challenges for the novel combination world and investors will share what they are looking for in their next combination investments. The event will help provide these converging industries with a roadmap for netherworld of – drugs, devices, and/or biologics. Come and bring your friends to get answers to questions like:
• What is a drug-device combination?
• What is the combination market potential?
• Does this have a significant effect on the way drugs and devices will be developed in the future? Can ‘intelligence’ be incorporated into the drug-device combinations?
• What are the regulatory, technical, clinical and funding challenges involved?
• What is the key for a successful and rapid regulatory process for combination product?
• What does a ‘combination entrepreneur’ look like?
• What are the possible Combination Product Strategies?

The Panel:
• Marc Galletti, Founder and Managing Director, Longitude Capital
• Vera Kallmeyer, MD, Ph.D., Founder and Managing Partner, Equity4health LLC
• Daniel Mufson, Ph.D., FAAPS, Chief Scientific Officer, Circle Medical Devices
• TBD

Moderator: Frank Rahmani, Partner, Cooley Godward Kronish LLP

WHEN: Thursday, May 17
6:00 - 7:00 pm: Networking and Business Showcase
7:00 - 8:15 pm: Panel discussion and Q/A
8:15 - 8:30 pm: Additional networking

LOCATION:
Cooley Godward Kronish LLP, 3175 Hanover Street, Palo Alto, CA 94304

PRE-REGISTERED RATES (All Rates Include Hors D’oeuvres):
Members - $20; Affiliates who advertise this event - $29; General Public - $49;
Business Showcase Exhibit Table - $149 (Includes exhibit table and two tickets to the event.)

WALK-IN RATES: Add $10.00 to the listed price

Seating is limited, so early registration is recommended to avoid disappointment on the day.

This event is co-sponsored by Cooley Godward Kronish LLP. Cooley Godward Kronish LLP.

Speaker Bios

Marc Galletti, Founder and Managing Director, Longitude Capital
Marc Galletti is a founder and Managing Director of Longitude Capital. He focuses on investments in medical devices and specialty pharmaceuticals including drug-device combinations. From 2003 to 2006, Mr. Galletti was a Senior Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Mr. Galletti worked with the same life sciences private equity team at both Amerindo Investment Advisors and Vector Fund Management where prior venture capital investments included Align Technology (NASDAQ: ALGN), CancerVax (acquired by Micromet), Eyetech Pharmaceuticals (NASDAQ: OSIP) and Theravance (NASDAQ: THRX). Mr. Galletti has also worked in the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his life sciences industry career 16 years ago at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals.

He currently serves on the boards of Altiva and Apneon. He is also a board observer at Aptus Endosystems, Broncus Technologies, Facet Solutions, MAP Pharmaceuticals, Sadra Medical and Sanarus Medical. He sits on the advisory boards for the Center of Biotechnology Management at the Kellogg School of Management and the Program for Biomedical Engineering at Brown University.

Mr. Galletti holds an M.B.A. from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.

Vera Kallmeyer, MD, Ph.D., Founder and Managing Partner, Equity4Health LLCDr. Kallmeyer is the Founder and Managing Partner of Equity4Health LLC, an early stage healthcare venture fund and of Veritas Venture Partners. She is also a Consulting Professor in the Department of Neurosurgery of Stanford Medical School, where she teaches courses on biomedical innovation, translational medicine and entrepreneurship. Formerly, she was Chief Financial Officer and Vice President of Corporate Development at Aviron (now Medimmune), a vaccine company, which she took public.

In addition, she has experience in investment banking with Wasserstein Perella & Company and Flemings as well as medical training in neurosurgery and cardiology. She attended Harvard Medical School and the Royal Postgraduate Medical School in London and holds MD and PhD degrees from the Friedrich Alexander University in Erlangen, Germany. She also received an MBA degree along with a Certificate in Public Management from the Stanford Graduate School of Business.

Dr. Kallmeyer serves or has served on the boards of several companies, including Entelos, Calypso Medical Technologies, Novasonics (now Zonare) and Northern Technologies International Corporation (NTI ?Amex). She also served on the boards of Redeon (now Biovalve), Neurovir (now Medigene), and iScribe (now Advanced PCS) until their respective acquisitions. In addition, she serves on the Board of Visitors and Scientific Advisory Board of UC Davis Medical School.

She is also active in the student- and start-up communities of Silicon Valley serving as a mentor to entrepreneurs. In this role she serves on the advisory board of START, a non-profit organization fostering entrepreneurship at European universities. She is an advisor to and frequent guest speaker at healthcare conferences both in the US and in Europe. Of particular interest to her are issues related to international venture capital and entrepreneurship, translational medicine, ethics related to new inventions in the biomedical field and the convergence of biotechnology, information technologies and physical sciences.

Daniel Mufson, Ph.D., FAAPS, Chief Scientific Officer, Circle Medical Devices
Dan is Chief Scientific Officer for Circle, a medical device engineering services and contract manufacturing firm, where he manages the drug delivery and combination product development efforts. Recent projects include: airway management, ophthalmic drug delivery and glucose monitoring systems. He was CSO at Alexza Pharmaceuticals where he led the development of the Staccato™ thermally generated aerosol platform for treatment of acute conditions. He has extensive experience with biologic, combination-product, device and product development and registration.

Frank F. Rahmani, Partner, Cooley Godward Kronish LLP
Frank F. Rahmani is a partner in the Cooley Godward Kronish Business department. Resident in the Palo Alto office, he has been with the Firm since 1997.

Mr. Rahmani has a general business and corporate law practice with an emphasis in the representation of emerging growth companies, intellectual property transactions, securities transactions, including private and public financing, and mergers and acquisitions.

Mr. Rahmani has counseled companies, entrepreneurs and investors in a broad range of matters including start-up formation and spin-off transactions, assistance with obtaining early stage financing, technology acquisition and licensing matters, to later stage financings, strategic and commercial relationships, variety of public offerings and mergers and acquisitions.

Mr. Rahmani counsels companies in a wide range of industries including medical devices and life sciences, software, semiconductor and telecommunication equipment.

Mr. Rahmani received a J.D., from Santa Clara University School of Law in 1997, where he was on the Deans’ List and was a representative to the American Bar Association. He received a business degree from Santa Clara University.

Prior to joining Cooley, Mr. Rahmani was an analyst with Intel Corporation working with the corporate finance and worldwide sales organizations.
Mr. Rahmani is a member of the State Bar of California.

Official Website: http://svase.org/index.php?option=com_extcalendar&Itemid=149&extmode=view&extid=896